EnVVeno Medical Corporation (NASDAQ:NVNO)

BRIEF

published on 04/09/2024 at 14:50, 7 months 14 days ago

EnVVeno Medical Appoints Andrew Cormack as Chief Commercial Officer to Spearhead VenoValve® Commercialization

EnVVeno Medical VenoValve® Chronic Venous Insufficiency (CVI) SAVVE U.S. Pivotal Study Commercialization Strategy
PRESS RELEASE

published on 04/09/2024 at 14:45, 7 months 14 days ago

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
enVVeno Medical Corporation appoints Andrew Cormack as Chief Commercial Officer to drive VenoValve's commercialization strategy. PMA application for FDA approval on track for Q4 2024

FDA Approval VenoValve EnVVeno Medical Corporation Commercialization Strategy Andrew Cormack
BRIEF

published on 03/15/2024 at 14:05, 8 months 8 days ago

EnVVeno Medical to Showcase Its Innovations in an Upcoming Virtual Investor Event

EnVVeno Medical Medical Innovation Virtual Investor Event Venous Disease Treatment Corporate Overview
PRESS RELEASE

published on 03/15/2024 at 14:00, 8 months 8 days ago

enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
enVVeno Medical to present at Virtual Investor Lunch Break on March 21, 2024, with CEO Robert Berman discussing the company's outlook and the enVVeno Opportunity

EnVVeno Medical Venous Disease Treatment Virtual Investor Lunch Break Robert Berman Bioprosthetic Solutions
BRIEF

published on 03/06/2024 at 14:45, 8 months 17 days ago

EnVVeno Medical Corporation Announces Positive Results from VenoValve Pivotal Trial

FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Clinical Improvement
PRESS RELEASE

published on 03/06/2024 at 14:40, 8 months 17 days ago

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
enVVeno Medical presents positive topline efficacy data from the SAVVE U.S. pivotal trial for the VenoValve at the 2024 American Venous Forum Annual Meeting, showing significant clinical improvement in CVI patients

EnVVeno Medical VenoValve Clinical Improvement SAVVE Trial CVI Patients
BRIEF

published on 02/29/2024 at 22:20, 8 months 23 days ago

EnVVeno Medical Reports Positive 2023 Financials and Clinical Progress

Medical Devices Clinical Trials Financial Results 2023 EnVVeno Medical VenoValve
PRESS RELEASE

published on 02/29/2024 at 22:15, 8 months 23 days ago

enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
enVVeno Medical Corporation reports $46.4 million in cash, progress towards the VenoValve U.S. pivotal trial, and financial results for 2023, anticipating value driving milestones in 2024

Financial Results Clinical Trials VenoValve EnVVeno Medical Corporation Value Driving Milestones
PRESS RELEASE

published on 02/20/2024 at 14:30, 9 months 3 days ago

Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
enVVeno Medical to present topline efficacy data from VenoValve U.S. pivotal trial at 2024 AVF Annual Meeting. VenoValve aims to address severe Chronic Venous Insufficiency with innovative bioprosthetic solutions

Clinical Trial EnVVeno Medical VenoValve Chronic Venous Insufficiency AVF Annual Meeting
BRIEF

published on 02/20/2024 at 14:30, 9 months 3 days ago

Promising Results for enVVeno Medical in the Treatment of Venous Insufficiency

EnVVeno Medical VenoValve RVCSS Chronic Venous Insufficiency Venous Treatment

Published on 11/22/2024 at 23:55, 1 day 1 hour ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 1 day 1 hour ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 1 day 2 hours ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 1 day 2 hours ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 1 day 2 hours ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 1 day 7 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 1 day 7 hours ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 1 day 7 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 1 day 8 hours ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 1 day 9 hours ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 1 day 10 hours ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 18 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 3 days 6 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 3 days 7 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 3 days 7 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News